The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 428-432

  Von Mehren, Margaret ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Adjuvant; Gastrointestinal stromal tumors; Imatinib; Neoadjuvant; Sunitinib

Indexed keywords

IMATINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LOW DRUG DOSE; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; WOUND INFECTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY;

EID: 47249141755     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328302ed82     Document Type: Review

References (25)

1. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histiogenesis. Am J Surg Pathol 1983; 7:507-519.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
3. von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2005; 19:547-564; vii.
4. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
5. Demetri G, vonMehren M, Blanke C, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
6. van Oosterom A, Judson I, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38:S83-S87.
7. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet 2004; 364:1127-1134.
8. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368:1329-1338.
9. Pierie J, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136:383-389.
10. DeMatteo R, Gold J, Saran L, et al. Tumor mitotic rate, size and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112:608-615. Single institution retrospective analysis of tumor characteristics associated with recurrence after initial primary GIST resection.
11. Eisenberg B, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11:465-474.
12. Dematteo R, Antonescu C, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. Am Soc Clin Oncol 2005; 23:9009.
13. DeMatteo R, Owzar K, Antonescu C, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000; Orlando. Florida: American Society of Clinical Oncology Gastrointestinal Cancer Symposium; 2008. First report of the therapeutic outcomes of ACOSOG Z9000, a nonrandomized trial of adjuvant imatinib in patients with resected high-risk GIST.
14. Nilsson B, Sjolund K, Kindblom L-G, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96:1656-1658. Single institution experience with adjuvant imatinib compared with a historical control. This is the first report that also includes data on the mutation status of each tumor.
15. DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 2007; 25:A10079. Initial presentation of ACOSG Z9001, a randomized prospective double blind placebo controlled trial of imatinib in the adjuvant setting demonstrating improved recurrence free survival in patients with GIST larger than 6 cm in size.
16. Blay J-Y, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2004; 16: 566-578.
17. McAuliffe JC, Lazar AJF, Yang D, et al. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 2007; 13:6727-6734.
18. Eisenberg B, Harris J, Blanke C, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (im) for advanced primary and recurrent operable gi stromal tumor (GIST) - early results of RTOG 0132; Chicago, IL: Surgical Society of Oncology; 2008. First abstract presenting the data from RTOG S0132, a prospective trial of neoadjuvant and adjuvant imatinib in patients with locally advanced, recurrent or metastatic disease that was deemed completely resectable at initial evaluation.
19. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325-2331.
20. Hohenberger P, Langer C, Pistorius S, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol 2006; 24:9500.
21. Andtbacka R, Ng C, Scaife C, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14-24. Single institution retrospective series of surgical outcomes following imatinib therapy in the locally advanced and metastatic disease setting.
22. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25:1107-1113. Prospective randomized trial demonstrating rapid recurrence of GISTs in patients treated with advanced imatinib for 1 year followed by discontinuation, even in the setting of complete surgical resection.
23. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689-695.
24. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093-1103.
25. Heinrich M, Corless C, Demetri G, et al. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.